InMed Pharmaceuticals Inc. (INM) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] InMed Pharmaceuticals Inc (INM) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, InMed is a tiny biotech company with early-stage drug programs, and right now the stock story is less about current business fundamentals and more about a merger that could almost completely reshape what shareholders actually own. > **📍 Basic Profile** > > Market Cap **$2.26 million** · Pharmaceuticals · NASDAQ NMS - GLOBAL MARKET · Price **$1.60** > **⚡ 3 Things You Should Know** > > 1. ⚠️ **Merger Changes the Whole Story:** The proposed all-stock merger with Mentari looks transformational, but existing InMed shareholders are expected to own only about **1.51%** of the combined company. In other words, buying INM today is basically a bet on the merger terms and post-deal company, not the old InMed by itself. > > 2. 🧪 **Science Pipeline, But No Real Operating Engine Yet:** The company has promising preclinical updates, including Alzheimer’s-related neuroinflammation data, but the financials still look like a classic development-stage biotech—negative margins, negative cash flow, and no meaningful earnings base yet. That means upside depends heavily on clinical progress and financing access. > > 3. 📉 **Balance Sheet Looks Clean, But Business Quality Looks Weak:** It has no debt and strong short-term liquidity on paper, which is better than many micro-cap biotechs. The catch is profitability is deeply negative, and the stock is still far below its **$7.98** 52-week high, which tells you the market remains skeptical despite the recent surge. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin **-170.07%**, ROE **-73.64%** | > | Growth Rate | Fast🚀 | 3-year revenue growth **65.52%**, but off a tiny base | > | Financial Health | Healthy💚 | Debt-to-equity **0**, current ratio **5.94** | > | Valuation | [Data unavailable] | PE **N/A** because earnings are negative | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Drug candidates are developed for patients with high unmet medical needs, with value creation expected to come from R&D progress, partnerships, licensing, or eventual commercialization rather than current product sales. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Drug development / pharma programs | [Data unavailable] | → | The company is still mainly an R&D story rather than a diversified revenue business | | Other / collaboration-related revenue | [Data unavailable] | [Data unavailable] | Revenue disclosure by segment was not provided in the dataset | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 29.73% | Below Average | There is some gross profit, but nowhere near enough to support operating costs | | Net Margin | -170.07% | Below Average | The company is losing far more than it earns, which is typical for early-stage biotech but still a major risk | | ROE | -73.64% | Average | Negative return on equity means shareholder capital is currently being consumed, not compounded | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth, but low quality | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What's important here is that the reported **3-year revenue growth of 65.52%** sounds exciting, but for a micro-cap biotech this can be misleading if the starting base was tiny or if revenue came from non-recurring items. Basically, this is not the kind of growth profile you’d treat like a scaling software or consumer business—it’s still mostly a pipeline-and-financing story. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with a decent cash cushion and no credit card debt, but no stable paycheck and ongoing monthly losses. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% | <60% safe | ✅Safe | | Current Ratio | 5.94 | >1.5 healthy | ✅Safe | | Cash Flow | Negative (cash flow/share **-2.20**) | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $0.575 - 52-Week High: $7.98 - Current: $1.60, **closer to the low than the high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(13.8% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE N/A | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE N/A | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Right now, the market is not valuing INM on earnings. It’s betting on some combination of merger completion, survival, pipeline optionality, and whether the post-deal entity can justify a much larger valuation than standalone InMed ever could. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05 | InMed agreed to merge with Mentari Therapeutics in an all-stock deal backed by **$290M** financing | Mixed: strategically important, but highly dilutive since pre-merger InMed holders are expected to own only **1.51%** | | 2026-05 | Reported Q3 FY2026 financial results and business update | Neutral to Negative: confirms it remains a development-stage biotech with weak current earnings power | | 2026-03 | Received Nasdaq notice regarding minimum bid price compliance | Negative: highlights listing-risk pressure common in distressed micro-caps | | 2026-03 | Announced positive preclinical data supporting INM-901 Alzheimer’s program | Positive: useful scientific validation, though still far from commercial proof | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 29.73% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -170.07% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -73.64% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | 3Y CAGR **65.52%** | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-09-30 | [Data unavailable] | -1.94 | [Data unavailable] | | 2024-06-30 | [Data unavailable] | -0.19 | [Data unavailable] | | 2024-03-31 | [Data unavailable] | -0.76 | [Data unavailable] | | 2022-06-30 | -111.10 | -280.60 | -152.6% Miss 😟 | **Earnings Trend Interpretation:** There isn’t enough complete estimate data here to judge a reliable beat-or-miss pattern. What we can say is the company has a history of losses, and the one visible surprise was a very large miss, which fits the profile of a volatile micro-cap biotech where quarterly numbers are not a strong anchor for valuation. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 3 firms | 37.5% | | Sell | 5 firms | 62.5% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No insider transaction data was provided. For a stock like this, insider buying would usually be a confidence signal, while insider selling after a sharp spike would be worth watching closely. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Merger Dilution Risk:** Existing shareholders are expected to own only **1.51%** of the combined company → If the deal closes as structured, legacy INM investors may see their economic interest heavily diluted. 2. **Execution/Clinical Risk:** Much of the bull case rests on early-stage drug development and preclinical momentum → If clinical progress stalls or data disappoints, the stock could lose support quickly. 3. **Listing and Micro-Cap Risk:** The company previously received a Nasdaq minimum bid price notice → If the share price weakens again, it could lead to compliance issues, reverse split risk, or reduced investor confidence. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** InMed is a micro-cap biotech with early-stage cannabinoid-related and neuroinflammation-focused drug programs, but the near-term equity story is now dominated by a proposed merger with Mentari. > > **Key strength:** The balance sheet is cleaner than many tiny biotechs—no debt and strong liquidity—and the merger brings a much larger financing package into the picture. > > **Key risk:** The biggest issue is that current shareholders appear set to own only a very small slice of the combined company, so the stock’s headline upside can be misleading if you don’t read the merger math. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis